Physician profile
Queenter M Kisang
NPI 1033773627
$1,827.27
in general payments reported to CMS, 2019-2025
23 companies · $1,375 in 2025
The $1,375 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $452 · 2025: $1,375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,827.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,827.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $304.57 | 2024-2025 | Caplyta |
| Novo Nordisk INC | $237.86 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $190.44 | 2024-2025 | Airsupra, Farxiga |
| Abbvie INC. | $132.59 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $103.11 | 2025 | |
| Aimmune Therapeutics, INC. | $86.30 | 2024-2025 | Zenpep |
| Dexcom, INC. | $74.73 | 2024-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $72.96 | 2025 | Repatha, Otezla, Evenity |
| Astellas Pharma US INC | $69.96 | 2024-2025 | Veozah |
| Axsome Therapeutics, INC. | $67.15 | 2024-2025 | Auvelity, Symbravo |
| Xeris Pharmaceuticals, INC. | $61.81 | 2025 | Gvoke Hypopen, Keveyis |
| Glaxosmithkline, LLC. | $57.13 | 2025 | Arexvy, Shingrix, Bexsero |
| Corcept Therapeutics | $56.79 | 2025 | Korlym |
| Sumitomo Pharma America, INC. | $50.30 | 2024 | Gemtesa |
| Viiv Healthcare Company | $37.65 | 2025 | Apretude |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $36.40 | 2024-2025 | |
| Exeltis, USA INC. | $34.31 | 2024-2025 | Slynd |
| Lilly USA, LLC | $33.46 | 2024-2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $31.14 | 2024-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $30.45 | 2025 | Hyqvia |
| Vertex Pharmaceuticals Incorporated | $26.98 | 2024 | |
| Organon LLC | $16.12 | 2025 | Nexplanon |
| Otsuka America Pharmaceutical, INC. | $15.06 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Queenter Kisang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.